Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05643131

Hyivy Device as Non-hormonal Therapy in Endometriosis

This study seeks to address accessible management of endometriosis-associated chronic pelvic pain by evaluating a novel device used in the home. The study is designed as a proof-of-concept single-arm pilot study, and the primary objective is to assess change in overall self-reported pelvic pain in people with endometriosis-associated chronic pelvic pain following the use of the Hyivy intravaginal device.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

McMaster University Medical Centre

Hamilton, Ontario, L8N 3Z5, Canada

About this study

Endometriosis is a chronic, inflammatory, estrogen-dependent disease characterized by ectopic growth of uterine-like cells outside the uterus. People living with endometriosis typically experience debilitating pelvic pain (dysmenorrhea, dyspareunia, dyschezia, dysuria, non-menstrual pelvic pain), and infertility. Endometriosis also has significant negative impacts on quality of life, physical, mental, and social wellbeing.

There is no diagnostic marker nor cure for this chronic disease. Current treatment options include medical therapies (mainly hormonal treatments aimed at suppressing menstruation or growth of the ectopic cells), surgery (to remove endometriotic lesions/nodules), and complementary or alternative therapies (non-medical or surgical options to manage symptoms; heat, mindfulness, diet, yoga, natural remedies, physical therapies, etc.).

Many people living with endometriosis report having used self-management strategies (complementary and alternative therapies) to manage their symptoms, and research on treatments and alternative therapies are consistently ranked among the top endometriosis research priorities. Alternative therapies have the potential to complement existing medical and surgical therapies, offering additional options to manage symptoms like pain.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1.Age ≥ 18 at the time of enrollment
  • 2.Generally in good health (other than due to endometriosis), at physician's discretion
  • 3.Diagnosed with endometriosis (clinical, radiologic, or surgical)
  • 4.Diagnosed with chronic pelvic pain (self-reported pain in pelvic area lasting >3 months)
  • 5.VAS for overall pelvic pain ≥ 4 at screening and baseline
  • 6.Medically managing endometriosis using continuous hormonal medications (i.e., oral contraceptive pills, progesterone only pills, Mirena, GnRH agonists/antagonists) for at least 3 months prior to enrollment
  • 7.Agrees not to commence any new treatments (medical or physical therapies) for the 12-week intervention period, including hormonal therapies for any medical condition, and complimentary and/or alternative management of surgery for endometriosis and associated chronic pain
  • 8.Agrees not to undergo pelvic physiotherapy with a trained professional during the study
  • 9.Agrees to avoid taking non-steroidal anti-inflammatory drugs (e.g., ibuprofen) for 72 hours before Visits 1, 2, and 3
  • 10.Must have the ability to charge the investigational device
  • 11.Must be willing and able to insert intravaginal device
  • 12.Able to understand, comply and consent to protocol requirements and instructions
  • 13.Able to attend scheduled study visits and complete required investigations

Exclusion criteria

  • 1.Chronic pelvic pain thought to be due to a condition other than endometriosis
  • 2.Diagnosis of premature ovarian insufficiency
  • 3.Any other medical condition or clinical finding giving reasonable suspicion of a disease or condition that contraindicates the use of the investigational product or that may affect the interpretation of the results or leave the patient at high risk from treatment complications, at the discretion of the investigator(s)
  • 4.Any surgery in the past 3 months or anticipates having surgery during the study
  • 5.Allergy to Hyivy device's materials
  • 6.Active vaginal infection (e.g. vulvovaginal candidiasis, trichomonas vaginitis, bacterial vaginosis, STIs) or infection in the pelvic area
  • 7.Current use of antibiotics and a history of vulvovaginal candidiasis
  • 8.Pregnant or lactating
  • 9.Currently under the care of a pelvic floor physiotherapist
  • 10.Have open wounds, cuts, or open sores present in vaginal or pelvic area
  • 11.Severe atrophic vaginitis or very dry, itchy, or sore vagina/vaginal area, at the discretion of the primary investigator(s)
  • 12.Hypoesthesia or loss in sensation of the pelvic floor
  • 13.Total and/or partial prolapse of the uterus and/or vagina
  • 14.Symptoms of severe urinary retention, severe extra-urethral incontinence or overflow incontinence
  • 15.Unable to position the device according to directions for use
  • 16.Use of any medical devices that may interfere with the investigational device's function, such as pacemakers, ventilators, and ear implants

Treatment and study plan

Hyivy Intravaginal Device

Device

Intravaginal use of Hyivy device three times per week for 12 weeks, with each session consisting of 10 minutes of heat (37-39ºC) and 10 minutes of dilation.

Primary outcomes

  1. Overall self-reported pelvic pain

    Time frame: Baseline, 6-weeks, 12-weeks

    Overall pelvic pain will be evaluated using a digital visual analog scale (VAS)

Secondary outcomes

  1. Site-specific tenderness and pelvic floor muscle pain

    Time frame: Baseline, 6-weeks, 12-weeks

    Site-specific tenderness and pelvic floor muscle pain will be measured by the Biberoglu and Behrman scale (B&B) ranging from 0 (none) to 15 (severe) and patient exams

  2. Quality of Life (EHP-30)

    Time frame: Baseline, 6-weeks, 12-weeks

    Changes in quality of life as assessed by the Endometriosis Health Profile-30 (EHP-30) ranging from 0 (best possible health status) to 100 (worst possible health status).

  3. Sexual Function (FSFI)

    Time frame: Baseline, 6-weeks, 12-weeks

    Changes in sexual function as assessed by the Female Sexual Function Index (FSFI). Scores range from 2 to 36 with higher scores indicating greater functioning.

  4. Safety and tolerability of the Hyivy device

    Time frame: Up to 12-weeks

    Occurrence of adverse events (AE) and serious adverse events (SAE).

  5. Adherence to study protocol

    Time frame: 6-weeks, 12-weeks

    Usage data collected by the Hyivy device will be used to assess participant adherence to the study regimen of 3 times/week device use.

  6. Feasibility of the Hyivy device

    Time frame: 6-weeks, 12-weeks

    Device usage will be assessed with a study-specific questionnaire.

  7. Use of rescue medication

    Time frame: Baseline, 6-weeks, 12-weeks

    Changes in the use of rescue medications for chronic pelvic pain, assessed with a study-specific questionnaire.

Other outcomes

  1. Autonomic function

    Time frame: Baseline, 6-weeks, 12-weeks

    Autonomic nervous system (ANS) function will be assessed using measures of heart rate variability (HRV) during a deep breathing test, active standing test, and water intake test.

  2. Peripheral gene expression

    Time frame: Baseline, 6-weeks, 12-weeks

    Changes in peripheral inflammation as assessed by a protein biomarker panel before and after device use

  3. Emergency room (ER) visits

    Time frame: Baseline, 6-weeks, 12-weeks

    Number of ER visits due to chronic pelvic pain in the last 6 weeks

  4. Device usability and patient satisfaction

    Time frame: 12-weeks

    Study-specific questionnaire to gather patient feedback

Study contacts

Contact information is provided by the study sponsor or research team.

Mathew Leonardi, M.D.

CONTACT

[email protected]

905-521-2100 ext. 76252

Sponsors and collaborators

Lead sponsor

Hyivy Health Inc

Industry

Collaborators

  • McMaster University

Registry information

Official study title

Evaluation of the Hyivy Device as a Non-hormonal Therapy in People With Endometriosis

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 8, 2022
Registry last updated
Sep 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.